Assay News and Research

RSS

BD Diagnostics receives 510(k) clearance to market GBS assay on BD MAX System

BD Diagnostics, a segment of BD, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the BD MAX™ GBS Assay for Group B Streptococcus on the BD MAX System. The BD MAX System is a next-generation automated workstation for molecular testing designed to streamline workflow and offer full walkaway automation to accommodate varying workloads for maximum lab efficiency and flexibility.

From BD (Becton, Dickinson and Company) 3 Jun 2010

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Chronix Biomedical today announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The "For Investigational Use Only" laboratory-based testing service uses Chronix's breakthrough approach—the Chronix Apoptotic DNA Blood Test—which analyzes apoptotic DNA from dead and dying cells to identify and track ongoing changes associated with specific cancers and other chronic diseases.

2 Jun 2010

Researchers develop new technique to detect cathepsin K in atherosclerosis, cancer metastasis

An enzyme implicated in osteoporosis, arthritis, atherosclerosis and cancer metastasis -- cathepsin K -- eluded reliable detection in laboratory experiments in the past. Now, a research team at the Georgia Institute of Technology has developed an assay that reliably detects and quantifies mature cathepsin K using a technique called gelatin zymography.

2 Jun 2010

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

Cancer diagnostics company Biomoda, Inc. and Obio, a corporation formed to pursue public and private funding for cancer research in Ohio, signed a memorandum of understanding to establish a CLIA-certified Biomoda clinical laboratory in Ohio to support ongoing research and development on Biomoda's porphyrin-based assay for the detection of early-stage cancer.

2 Jun 2010

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has obtained a non-exclusive license to incorporate the BRAF V600E mutation sequence into Asuragen's molecular diagnostic products. The license was obtained from Johns Hopkins University and includes the use of the BRAF V600E mutation as a component of diagnostic test kits and for use in Asuragen's CLIA laboratory for clinical research and patient testing.

2 Jun 2010

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.

2 Jun 2010

Oncimmune develops new blood test to aid early detection of cancer

The University of Nottingham spin-out company, Oncimmune Ltd, has developed a ground breaking blood test which will aid the detection of cancer as much as five years earlier than current testing methods such as mammography and CT scans. Physicians will know the result of their patient's test within one week of sending in a blood sample to Oncimmune.

2 Jun 2010

Amorfix provides update on development of blood test for vCJD

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, provides an update on the development of a blood test for vCJD, one of its six product development programs.

31 May 2010

Hitachi Software, OriGene announce co-marketing agreement

Hitachi Software Engineering America, Ltd. and OriGene Technologies, Inc. today announced a co-marketing agreement to jointly promote OriGene's multiplex assays built on Luminex xMAP/Bio-Plex technology and Hitachi Software's MasterPlex software suite for analysis and reporting of multiplex assay data.

29 May 2010

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

Roche Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Premarket Approval for its Elecsys Antibody to hepatitis C virus (anti-HCV) assay. The Elecsys Anti-HCV assay is an in-vitro diagnostic test for the qualitative detection of total antibodies to hepatitis C virus in human serum or plasma.

From Roche Sequencing and Life Science 28 May 2010

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia, an inherited condition that can lead to bone marrow failure and cancer.

28 May 2010

Celsis International updates Drug Master Files with FDA

Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.

28 May 2010

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

Pacific Biomarkers, Inc. has been awarded a contract by a leading multinational pharmaceutical company to provide essential laboratory data for an adaptive Phase I cardiovascular trial. This study is part of a major drug-development program to evaluate an innovative new treatment to reduce recurrent cardiovascular events associated with acute coronary syndrome.

27 May 2010

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $9.5 million grant for the continuation of its Diabetes Research and Training Center (DRTC). The DRTC was also awarded a $632,000 supplemental grant for equipment and additional pilot and feasibility studies through the American Recovery and Reinvestment Act (ARRA), bringing total NIH support to $10,177,000.

26 May 2010

QIAGEN acquires rights to 70 molecular food safety tests developed by Institute for Product Quality

QIAGEN today announced that it has entered into an agreement with the Institute for Product Quality (ifp), pursuant to which QIAGEN has acquired all rights to 70 molecular food safety tests developed by the Berlin-based specialized laboratory center for food analysis.

From QIAGEN Manchester Limited 26 May 2010

Influenza A(H1N1) appears milder than seasonal flu in tropical environment: Report

In a tropical environment, influenza A(H1N1) appeared milder than seasonal flu, was less likely to cause fever and upset stomach and more likely to infect younger individuals, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

25 May 2010

Northrop Grumman begins delivery of critical assay technology to DHS for homeland defense applications

Northrop Grumman Corporation has begun deliveries of critical assay technology to the U.S. Department of Homeland Security as part of the company's BioWatch Gen-3 contract to develop a new generation of biological detectors for homeland defense applications.

25 May 2010

Abviva receives new patent grant notifications for MSA technology

Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.

24 May 2010

New England Peptide launches NEPTune line of custom proteomics reagents

New England Peptide (NEP) today introduced NEPTune TM, a new proprietary line of custom proteomics reagents to help its customers to quickly and inexpensively maximize biomarker assay development and produce consistent results.

21 May 2010

COTI reports positive results from first phase of HIV integrase inhibitor discovery program

Critical Outcome Technologies Inc. today announced positive results from the first phase of its HIV integrase inhibitor discovery program. These results provide novel intellectual property to the Company and further validation of the CHEMSAS® drug discovery technology.

21 May 2010

Assay News and Research

BD Diagnostics receives 510(k) clearance to market GBS assay on BD MAX System

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Researchers develop new technique to detect cathepsin K in atherosclerosis, cancer metastasis

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

Oncimmune develops new blood test to aid early detection of cancer

Amorfix provides update on development of blood test for vCJD

Hitachi Software, OriGene announce co-marketing agreement

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Celsis International updates Drug Master Files with FDA

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

QIAGEN acquires rights to 70 molecular food safety tests developed by Institute for Product Quality

Influenza A(H1N1) appears milder than seasonal flu in tropical environment: Report

Northrop Grumman begins delivery of critical assay technology to DHS for homeland defense applications

Abviva receives new patent grant notifications for MSA technology

New England Peptide launches NEPTune line of custom proteomics reagents

COTI reports positive results from first phase of HIV integrase inhibitor discovery program

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News